CARCINOMA, RENAL CELL
Clinical trials for CARCINOMA, RENAL CELL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, RENAL CELL trials appear
Sign up with your email to follow new studies for CARCINOMA, RENAL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug enters first human tests for multiple advanced tumors
Disease control TerminatedThis early-phase study aimed to test the safety, side effects, and best dose of an experimental drug called QEQ278 in adults with advanced solid tumors. It enrolled 30 participants with specific advanced cancers (lung, kidney, esophageal, or head/neck) that had progressed despite…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 23:11 UTC
-
Experimental drug tested as last hope for rare, Tough-to-Treat cancers
Disease control TerminatedThis study tested whether a drug called SGI-110 could shrink or slow the growth of certain rare cancers, including specific types of stomach, adrenal, and kidney tumors. It was for patients aged 12 and older whose cancers had not responded to standard treatments. Participants rec…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo therapy trial for Tough-to-Treat kidney cancer
Disease control TerminatedThis study tested whether adding the immunotherapy drug atezolizumab to the targeted therapy cabozantinib works better than cabozantinib alone for people with advanced kidney cancer. It was for patients whose cancer had started growing again after a previous type of immunotherapy…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Novartis halts early trial of new cancer drug for business reasons
Disease control TerminatedThis was an early safety study for a new drug called DFF332, designed to block a protein that helps certain cancers grow. It was tested alone and in combinations with other cancer drugs in adults with advanced kidney cancer and other tumors driven by specific genetic changes. The…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Terminated trial tests Last-Chance drugs for tough kidney cancers
Disease control TerminatedThis study tested two different drug combinations for people with advanced kidney cancer that had stopped responding to standard treatments. The trial aimed to find safe doses and see if these combinations could shrink tumors or slow disease progression. The study was terminated …
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC